Your browser doesn't support javascript.
loading
Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer.
Lee, Sung Uk; Kim, Jae-Sung; Kim, Young Seok; Cho, Jaeho; Choi, Seo Hee; Nam, Taek-Keun; Jeong, Song Mi; Kim, Youngkyong; Choi, Youngmin; Lee, Dong Eun; Park, Won; Cho, Kwan Ho.
Afiliação
  • Lee SU; The Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Kim JS; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Kim YS; Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Cho J; Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Choi SH; Department of Radiation Oncology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
  • Nam TK; Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun, Korea.
  • Jeong SM; Department of Radiation Oncology, Ewha Womans University Medical Center, Ewha Womans University College of Medicine, Seoul, Korea.
  • Kim Y; Department of Radiation Oncology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea.
  • Choi Y; Department of Radiation Oncology, Dong-A University Hospital, Dong-A University School of Medicine, Busan, Korea.
  • Lee DE; Biostatistics Collaboration Team, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Park W; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Cho KH; The Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Cancer Res Treat ; 54(4): 1191-1199, 2022 Oct.
Article em En | MEDLINE | ID: mdl-34883554
PURPOSE: This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer. MATERIALS AND METHODS: Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters. RESULTS: When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%. CONCLUSION: A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Cancer Res Treat Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Cancer Res Treat Ano de publicação: 2022 Tipo de documento: Article